Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Corporate
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
22 Nov 2018 - 23 Nov 2018
Salon Actionaria 2018, Paris, France
09 Oct 2018
Chardan 2nd Annual Genetic Medicines Conference, NYC (US)
25 July 2018
GenSight Biologics Reports Interim Financial Results for the First Half of 2018
20 Jul 2018
Ophthalmology Innovation Summit @ RETINA, Vancouver (BC), Canada
25 April 2018
GenSight Biologics reports €49 million cash position as of March 31, 2018 and provides update on GS010
28 February 2018
GenSight Biologics Reports Full Year 2017 Financial Results
25 January 2018
GenSight Biologics reports €55 million 2017 year-end cash position and provides corporate update
25 January 2018
GenSight Biologics Appoints Julio Benedicto as Vice President of Marketing
06 November 2017
GenSight Biologics to Participate in Multiple Conferences in November
26 October 2017
GenSight Biologics Reports its Cash Position as of September 30, 2017
View previous 9 articles
1
…
9
10
11
12
13
14
15
16
View next 9 articles
Go back to the page of the page